Several active immune markers were uniquely elevated in non-HET posttreatment tumors, including CD20 (tumor ROI) and CD8 (immune ROI), indicating increased CD8+ T cell and B cell infiltration after treatment (Supplemental Figure 8B). Here, CD8A is linked to neoplasm.